Q-omics provides the consensus-scored AK1 profile across patient tissues and cancer cell-line models. AK1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, AK1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, AK1 protein abundance shows 32,896 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight STAD, KIRC, and HNSC as cancer lineages where AK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AK1 survival associations across molecular data types. AK1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AK1 RNA expression–survival associations across cancer types. High AK1 expression shows unfavorable associations in ACC, KICH, KIRC, LUSC and BRCA, but favorable associations in STAD. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for AK1 RNA expression.
This table summarizes AK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for AK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AK1 shows lower tumor expression in KIRC, LUAD, LUSC and UCEC and higher tumor expression in THCA and LIHC. The KIRC box plot shows higher AK1 RNA expression in normal versus tumor tissue (log2 FC = −1.004, t-test p < 0.001).
This table shows molecular features associated with AK1 in patient tissues and cancer cell lines. In patient samples, AK1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, AK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
